Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Biopharmaceuticals
10%
C4BP
10%
CD20
20%
Cell-based
10%
Cell-to-cell
10%
Chemotherapy-free Regimens
20%
Clinical Practice
10%
Complement Activation
50%
Concept Development
20%
Conventional Chemotherapy
10%
Development Program
10%
Development Strategy
10%
Direct Cytotoxicity
20%
Factor H Binding Protein
10%
Further Development
10%
High Efficacy
20%
Human Epidermal Growth Factor Receptor 2 (HER2)
30%
Immunoconjugate
50%
Immunotherapeutic Strategy
10%
Immunotherapeutics
50%
Immunotherapy Strategy
50%
Increasing Prevalence
10%
Innovative Strategies
10%
Liquid Tumor
20%
Local Complementation
20%
Lymphoma
10%
Lymphoma Cells
10%
Multimers
50%
Multivalent
10%
New Therapeutic Approaches
10%
NK Cell Activity
10%
Phagocytosis
10%
Safety Assessment
50%
Solid Tumors
10%
Standard of Care
10%
Technical Platform
20%
Therapeutic Efficacy
10%
Therapeutic Evaluation
50%
Therapeutic Monoclonal Antibody
20%
Tumor
30%
Tumor Cell Targeting
20%
Tumor Cells
10%
Tumor Model
10%
Two's Complement
20%
Unmet Medical Need
10%
Xenograft Model
10%
Immunology and Microbiology
Antibody Conjugate
100%
CD20
40%
Cell Activation
20%
Cell Phagocytosis
20%
Complement Activation
100%
Concept Formation
20%
Cytotoxicity
20%
Factor H
20%
Immunotherapy
100%
Lymphoma Cell
20%
Monoclonal Antibody
20%
Natural Killer Cell
20%
Prevalence
20%
Tumor Cell
40%
Xenograft
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antibody Conjugate
100%
Chemotherapy
33%
Combination Therapy
16%
Complement Factor H
16%
Cytotoxicity
16%
Immunotherapy
100%
Monoclonal Antibody
16%
Neoplasm
100%
Prevalence
16%
Solid Malignant Neoplasm
16%
Tumor Model
16%